Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke

Stroke

Volumn 34, Issue 7, 2003, Pages 1790-1795

  Zhang, Li ^a   Zhang, Zheng Gang ^a   Zhang, Rui Lan ^a   Lu, Mei ^b   Krams, Michael ^c   Chopp, Michael ^a,d  

^a HENRY FORD HOSPITAL   (United States)

^b HENRY FORD HEALTH SCIENCES CENTER   (United States)

^c PFIZER INC   (United States)

^d OAKLAND UNIVERSITY   (United States)

Author keywords

Neuroprotection; Rats; Reperfusion injury; Stroke; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; CD11B ANTIGEN; CD18 ANTIGEN; FIBRINOLYTIC AGENT; NEUROPROTECTIVE AGENT; NEUTROPHIL INHIBITORY FACTOR; UK 279276;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EMBOLISM; BRAIN FUNCTION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FIBRIN DEPOSITION; FIBRINOLYTIC THERAPY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NEUTROPHIL; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; RAT; STROKE;

ANIMALS; ANTIGENS, CD11B; BODY WEIGHT; BRAIN; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DISEASE MODELS, ANIMAL; FIBRIN; GLYCOPROTEINS; HELMINTH PROTEINS; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INTRACRANIAL EMBOLISM; MALE; MEMBRANE PROTEINS; NEUROLOGIC EXAMINATION; NEUROPROTECTIVE AGENTS; PEROXIDASE; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0038506990     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000077016.55891.2E     Document Type: Article

References (31)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Fieschi C, Toni D, LeSaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Magagne M, Hennerici M, for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA. 1995;274:1017-1025.
3. Zivin JA. Thrombolytic stroke therapy: past, present, and future. Neurology. 1999;53:14-19.
4. Jean WC, Spellman SR, Nussbaum ES, Low WC. Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Neurosurgery. 1998;43:1382-1396; comment 1396-1397.
5. Hallenbeck JM, Dutka AJ, Tanishima T, Kochanek PM, Kumaroo KK, Thompson CB, Obrenovitch TP, Contreras TJ. Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period. Stroke. 1986;17:246-253.
6. Zhang RL, Zhang ZG, Chopp M. Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat. Neurology. 1999;52:273-279.
7. Becker KJ. Inflammation and acute stroke. Curr Opin Neurol. 1998;11:45-49.
8. Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke. 1992;23:1367-1379.
9. Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol. 1995;57:827-872.
10. Zhang ZG, Chopp M, Tang WX, Jiang N, Zhang RL. Postischemic treatment (2-4 h) with anti-CD11b and anti-CD18 monoclonal antibodies are neuroprotective after transient (2 h) focal cerebral ischemia in the rat. Brain Res. 1995;698:79-85.
11. Zhang RL, Chopp M, Li Y, Zaloga C, Jiang N, Jones ML, Miyasaka M, Ward PA. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology. 1994;44:1747-1751.
12. Emerich DF, Dean RL III, Bartus RT. The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct? Exp Neurol. 2002;173:168-181.
13. Moyle M, Foster DL, McGrath DE, Brown SM, Laroche Y, De Meutter J, Stanssens P, Bogowitz CA, Fried VA, Ely JA, et al. A hookworm glycoprotein that inhibits neutrophil function is a ligand of the integrin CD11b/CD18. J Biol Chem. 1994;269:10008-10015.
14. Muchowski PJ, Zhang L, Chang ER, Soule HR, Plow EF, Moyle M. Functional interaction between the integrin antagonist neutrophil inhibitory factor and the I domain of CD11b/CD18. J Biol Chem. 1994;269:26419-26423.
15. Jiang N, Chopp M, Chahwala S. Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat. Brain Res. 1998;788:25-34.
16. Zhang RL, Zhang ZG, Chopp M, Zivin JA. Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke. 1999;30:624-629.
17. Bowes MP, Rothlein R, Fagan SC, Zivin JA. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology. 1995;45:815-819.
18. Zhang RL, Chopp M, Zhang ZG, Jiang Q, Ewing JR. A rat model of embolic focal cerebral ischemia. Brain Res. 1997;766:83-92.
19. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, Chopp M. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke. 2001;32:1005-1011.
20. Hernandez TD, Schallert T. Seizures and recovery from experimental brain damage. Exp Neurol. 1988;102:318-324.
21. Zhang ZG, Chopp M. Measurement of myeloperoxidase immunoreactive cells in ischemic brain after transient middle cerebral artery occlusion in the rat. Neurosci Res Comm. 1997;20:85-91.
22. Zhang ZG, Zhang L, Tsang W, Goussev A, Powers C, Ho K, Morris D, Smyth SS, Coller BS, Chopp M. Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion. Brain Res. 2001;912:181-194.
23. Prestigiacomo CJ, Kim SC, Connolly ES Jr, Liao H, Yan SF, Pinsky DJ. CD18-mediated neutrophil recruitment contributes to the pathogenesis of reperfused but not nonreperfused stroke. Stroke. 1999;30:1110-1117.
24. Grotta J. Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke. 2002;33:306-307.
25. del Zoppo GJ, Hallenbeck JM. Advances in the vascular pathophysiology of ischemic stroke. Thromb Res. 2000;98:73-81.
26. Chopp M, Zhang RL, Zhang ZG, Jiang Q. The clot thickens: thrombolysis and combination therapies. Acta Neurochir Suppl. 1999;73:67-71.
27. Rieu P, Sugimori T, Griffith DL, Arnaout MA. Solvent-accessible residues on the metal ion-dependent adhesion site face of integrin CR3 mediate its binding to the neutrophil inhibitory factor. J Biol Chem. 1996;271:15858-15861.
28. Gautam N, Olofsson AM, Herwald H, Iversen LF, Lundgren-Akerlund E, Hedqvist P, Arfors KE, Flodgaard H, Lindbom L. Heparin-binding protein (HBP/CAP37): a missing link in neutrophil-evoked alteration of vascular permeability. Nat Med. 2001;7:1123-1127.
29. Hunter AJ, Mackay KB, Rogers DC. To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents? Trends Pharmacol Sci. 1998;19:59-66.
30. Berger C, Fiorelli M, Steiner T, Schabitz WR, Bozzao L, Bluhmki E, Hacke W, von Kummer R. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke. 2001;32:1330-1335.
31. Goel MS, Diamond SL. Neutrophil enhancement of fibrin deposition under flow through platelet-dependent and -independent mechanisms. Arterioscler Thromb Vasc Biol. 2001;21:2093-2098.